Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso

NCT03950739 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT03950739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03950739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
Lead sponsor
United Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
September 17, 2019
Completion date
August 22, 2023
Enrollment
51 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension